Ruben A. Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center

Expert panelists review important disease-related and patient-related factors when considering bone marrow transplant in patients with primary myelofibrosis.

Pankit Vachhani, MD, guides a discussion on the FDA approval of fedratinib and reviews how it has affected the therapeutic landscape for patients with primary myelofibrosis.

MPN expert Srdan Verstovsek, MD, PhD, shares insights into the role of ruxolitinib for the treatment of myelofibrosis.

An expert in the management of myeloproliferative neoplasms, Jamile Shammo, MD, FASCP, FACP, leads a discussion on best practices for assessing response and monitoring for progression.

Pankit Vachhani, MD, reviews recent changes to the NCCN Guidelines, highlighting the addition of luspatercept for the treatment of primary myelofibrosis.

Key opinion leaders in the management of myeloproliferative neoplasms review factors to consider when selecting treatments for patients and highlight the role of fedratinib in the first- or second-line settings.

A panel of experts in myeloid malignancies begins with a discussion on risk assessment criteria, next-generation sequencing, and symptom burden questionnaires to assess prognosis for patients with myelofibrosis.

Unmet needs and current areas that are being studied in in essential thrombocythemia.

Pankit Vachhani, MD, highlights treatment considerations in low- to high-risk essential thrombocythemia and patients resistant or intolerant to hydroxyurea. 

Expert discusses risk-stratification models, prognosis, and the management of complications in essential thrombocythemia.

Key opinion leaders discuss the current unmet needs in myelofibrosis and ongoing approaches to look forward to in hopefully overcoming these challenges.

Srdan Verstovsek, MD, PhD, briefly reviews the role of pacritinib in patients with myelofibrosis as well as the PACIFICA study.

Experts discuss the role of transplant and evaluating options in patients with myelofibrosis. 

A review of data from the COMFORT trials and the management and real-world use of ruxolitinib in patients with myelofibrosis, also touching on its use during the coronavirus pandemic.

Srdan Verstovsek, MD, PhD, reviews data from the JAKARTA and JAKARTA2 clinical trials as well as his approach to using fedratinib in his own clinical practice. 

Ruben A. Mesa, MD, and Srdan Verstovsek, MD, PhD, provide insight on the disease burden and prognostic scoring of primary myelofibrosis, as well as options for nontransplant candidates.

Srdan Verstovsek, MD, PhD, shares how he assesses and typically starts treatment in patients with low-risk primary myelofibrosis, looking specifically at whether patients are symptomatic or asymptomatic. 

What to look forward to in the polycythemia vera space, including new clinical trials.

Experts give real-world insight in using ruxolitinib in patients with polycythemia vera. 

Experts discuss clinical trial updates in polycythemia vera, including data from RESPONSE, RESPONSE-2, an international observational study of ruxolitinib, and REVEAL.

Ruben A. Mesa, MD, highlights signs of disease progression and the utilization of guideline recommendations in the occurrence of a thrombotic event when treating polycythemia vera.

Key opinion leaders discuss treatment goals, considerations, and guideline recommendations for patients with low- or high-risk polycythemia vera.

Evaluating treatment, diagnostic criteria, and risk-assessment tools in polycythemia vera.

Srdan Verstovsek, MD, PhD, provides an overview of the similarities and differences between myeloproliferative neoplasms, including polycythemia vera, myelofibrosis, and essential thrombocythemia.

Experts provide insight on therapeutic approaches of myeloproliferative neoplasms, highlighting clinical trial data and disease characteristics of polycythemia vera, primary myelofibrosis, and essential thrombocythemia.